Proactiveinvestors USA & Canada CB2 Insights https://www.proactiveinvestors.com Proactiveinvestors USA & Canada CB2 Insights RSS feed en Fri, 24 May 2019 04:12:09 -0400 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) <![CDATA[News - CB2 Insights announces new ticker symbol on OTC markets ]]> https://www.proactiveinvestors.com/companies/news/220522/cb2-insights-announces-new-ticker-symbol-on-otc-markets-220522.html CB2 Insights (CSE:CBII) (OTCMKTS:CBIIF) announced Friday that it has changed its OTCQB ticker symbol to “CBIIF.”

The cannabis data analytics company will continue to trade on the Canadian Securities Exchange under the symbol “CBII.”

READ: CB2 Insights strengthens board with new member and appoints chairman

Based in Toronto, CB2 Insights is a medical cannabis-focused data firm. The company is busy meeting what it says is significant demand by building a data asset covering the medical cannabis sector by providing predictive analytics tools, data-driven software and services. In addition, it operates 28 cannabis evaluation and education clinics in 12 US states.

CB2 Insights said in a statement Friday that no action is required by shareholders in connection with the ticker symbol change.

Shares of CB2 closed Thursday up 2% to C$0.26 on the Canadian Securities Exchange and were trading at US$0.20 on the OTCQB.  

Contact Angela at angela@proactiveinvestors.com

Follow her on Twitter @AHarmantas

]]>
Fri, 17 May 2019 08:39:00 -0400 https://www.proactiveinvestors.com/companies/news/220522/cb2-insights-announces-new-ticker-symbol-on-otc-markets-220522.html
<![CDATA[News - CB2 Insights strengthens board with new member and appoints chairman ]]> https://www.proactiveinvestors.com/companies/news/219603/cb2-insights-strengthens-board-with-new-member-and-appoints-chairman-219603.html CB2 Insights (CSE:CBII) (OTCMKTS:CBTOF) has added two new members to its board of directors and appointed a new chairman.

The cannabis data analytics company announced that it is welcoming Marc Adelson, deputy chief legal officer at Teladoc Inc, to its board of directors.

Current board member David Danzinger was named the company’s chairman.

READ: CB2 Insights closes acquisition of cannabis evaluation clinics in Arizona and Colorado

Adelson is the deputy chief legal officer at Teladoc Inc, a New York-based telemedicine company. He has spent nearly a decade with the health care technology firm, which connects healthcare professionals with patients.

“I have been a part of leading edge health care delivery and technology companies for quite some time, and I am thrilled to be able to lend my knowledge to CB2 Insights on the Board,” said Adelson. “I immediately recognized how critical CB2’s role is in understanding medical cannabis prescribing and efficacy and am excited to be a part of that evolution.”

New chairman Danzinger is the senior vice president, assurance and national leader, public companies at accounting firm MNP. He has been on CB2’s board since 2017.

“With the addition of Marc and now with David as our Chairman, we are proud of the diverse strength our Board is taking,” said Prad Sekar, CEO of CB2 Insights. “We are entering an exciting and pivotal time at CB2 as our clinical operations continue to expand and our data asset continues to grow in its value to a large number of stakeholders throughout the traditional health care industry.”

New nomination process

Toronto-based CB2 also announced it had adopted a bylaw to establish a framework for advance notice of nominations of directors by the CB2 shareholders.

The bylaw sets a procedure requiring advance notice by any shareholder who intends to nominate someone for election as a director and sets a deadline for shareholders to notify the company in writing ahead of nomination.

Shares of CB2 were trading at C$0.28 in Canada and US$0.21 in the US on Thursday morning.

Contact Angela at angela@proactiveinvestors.com

Follow her on Twitter @AHarmantas

]]>
Thu, 02 May 2019 12:01:00 -0400 https://www.proactiveinvestors.com/companies/news/219603/cb2-insights-strengthens-board-with-new-member-and-appoints-chairman-219603.html
<![CDATA[News - CB2 Insights closes acquisition of cannabis evaluation clinics in Arizona and Colorado ]]> https://www.proactiveinvestors.com/companies/news/218324/cb2-insights-closes-acquisition-of-cannabis-evaluation-clinics-in-arizona-and-colorado-218324.html CB2 Insights Inc (CSE:CBII) announced Wednesday that it had finalized the acquisition of MedEval Clinic LLC as the data analytics company continues to bolster its presence in southwestern United States.

MedEval Clinic runs a network of health centres in the states of Colorado and Arizona that offer cannabis evaluation and educational services. The company reported around C$1 million in revenue last year.

READ: CB2 Insights acquires Colorado-based Relaxed Clarity in a cash and stock deal; shares rise

CB2 acquired MedEval in a combination of cash and stock with CB2 shelling out US$150,000 in cash as well as 450,000 of its shares worth a deemed value of US$225,000. Additional milestone incentives are in place, which are valued at up to US$300,000.

The new acquisition is in line with CB2’s clinical consolidation strategy, according to CEO Prad Sekar.

“With the completion of this additional 2019 acquisition, CB2 continues to solidify our position as the leading group of multi-state medical cannabis evaluation and education centers in the US,” said CB2’s Sekar.

“These acquisitions not only bring meaningful lift to our top line revenue, they are key to growing our data pool as more and more stakeholders are looking for clinically-validated, evidence-based data to assess the true efficacy of cannabis treatment globally.”

CB2 concentrates on gleaning real-world evidence obtained from data outside randomized trials and generated during routine clinical practice. The company has created what it says are game-changing tools that engage the medical community and provide the data doctors and other professionals need to recommend with confidence cannabis-based medicines.

The Toronto-based company currently evaluates 65,000 patients annually through its clinic network and handles millions of clinically validated data points to advance understanding of the effectiveness and risks associated with cannabinoid therapy.

Shares of CB2 closed at C$0.31 on Tuesday in Toronto.

Ellen Kelleher also contributed to this report

Contact Angela at angela@proactiveinvestors.com

Follow her on Twitter @AHarmantas

]]>
Wed, 10 Apr 2019 08:24:00 -0400 https://www.proactiveinvestors.com/companies/news/218324/cb2-insights-closes-acquisition-of-cannabis-evaluation-clinics-in-arizona-and-colorado-218324.html
<![CDATA[Media files - Buds & Duds: Cannabis stocks slide on Thursday; CB2 Insights shares pop on acquisition ]]> https://www.proactiveinvestors.com/companies/stocktube/12879/buds--duds-cannabis-stocks-slide-on-thursday-cb2-insights-shares-pop-on-acquisition-12879.html Thu, 04 Apr 2019 15:44:00 -0400 https://www.proactiveinvestors.com/companies/stocktube/12879/buds--duds-cannabis-stocks-slide-on-thursday-cb2-insights-shares-pop-on-acquisition-12879.html <![CDATA[Media files - CB2 Insights adds another asset with acquisition of Colorado based Relaxed Clarity. ]]> https://www.proactiveinvestors.com/companies/stocktube/12875/cb2-insights-adds-another-asset-with-acquisition-of-colorado-based-relaxed-clarity-12875.html Thu, 04 Apr 2019 12:34:00 -0400 https://www.proactiveinvestors.com/companies/stocktube/12875/cb2-insights-adds-another-asset-with-acquisition-of-colorado-based-relaxed-clarity-12875.html <![CDATA[News - CB2 Insights acquires Colorado-based Relaxed Clarity in a cash and stock deal; shares rise ]]> https://www.proactiveinvestors.com/companies/news/217993/cb2-insights-acquires-colorado-based-relaxed-clarity-in-a-cash-and-stock-deal-shares-rise-217993.html CB2 Insights Inc (CSE:CBII) strengthened its US presence with the acquisition of Colorado-based medical cannabis clinic group Rae of Sunshine Health Services (ROSH) LLC, it announced on Thursday.

Under the terms of the acquisition, CB2 acquired 100% of ROSH and its subsidiaries for a combination of cash and stock, including a cash payment of US$200,000 and the issuance of 500,000 CB2 shares, in a deal worth around US$850,000 total.

Shares of CB2 powered over 5% higher to C$0.31 by midday Thursday on the back of the news.

READ: CB2 Insights strikes deal to acquire MedEval Clinic

Rae of Sunshine, operating under the name Relaxed Clarity, operates four clinics in Colorado. Last year the company posted nearly US$1.1 million in revenue.

“Based on 2018 revenue results of this acquisition, CB2 Insights is currently on track to achieve at least C$12.2 million in revenue for 2019,” said Prad Sekar, CEO at CB2 Insights. “We have an active pipeline of acquisition targets and along with organic growth within our existing operations.”

The Toronto-based data analytics company anticipates achieving its stated 2019 revenue goal of more than C$20 million, for year-over-year growth of more than 80% compared to 2018, it said in a statement.

CB2 gathers data and creates objective evidence in an effort to bring medical cannabis into traditional health care.

In March, the company acquired MedEval Clinic LLC, a medical cannabis evaluation and education center group with locations in Colorado and Arizona.

--Updated to reflect current share price--

Contact Angela at angela@proactiveinvestors.com

Follow her on Twitter @AHarmantas

 

]]>
Thu, 04 Apr 2019 12:04:00 -0400 https://www.proactiveinvestors.com/companies/news/217993/cb2-insights-acquires-colorado-based-relaxed-clarity-in-a-cash-and-stock-deal-shares-rise-217993.html
<![CDATA[News - Buds & Duds: Cannabis stocks slide on Thursday; CB2 Insights shares pop on acquisition ]]> https://www.proactiveinvestors.com/companies/news/217994/buds--duds-cannabis-stocks-slide-on-thursday-cb2-insights-shares-pop-on-acquisition-217994.html Cannabis stocks tripped on Thursday after significant gains on Wednesday. While the majority of cannabis players have had a bumping 2019 when it comes to stock prices, concerns remain about what lies ahead. 

The North American Marijuana Index, which tracks the top cannabis stocks in the US and Canada, dropped 1% to 305.61. The Horizons Marijuana Life Sciences Index ETF was down 0.7% at C$21.57. 

Buds 

CB2 Insights (CSE:CBII) shares soared on Thursday after the medical cannabis-focused data firm announced it has acquired the assets of Colorado-based medical cannabis clinic group Rae of Sunshine Health Services LLC, operating as Relaxed Clarity. 

Shares of the Toronto-based company were up 8.5% at C$0.32. 

WATCH: CB2 Insights adds another asset with acquisition of Colorado based Relaxed Clarity

International Cannabis Corp (CSE:WRLD.U) (OTCMKTS:WLDCF) shares were bolstered Thursday by the news that it may soon be listed on a major international exchange. 

The cannabis company is pursuing a public listing on either the Nasdaq, the New York Stock Exchange or the AIM in London.

Shares were up 4.2% at US$0.32 in New York. 

READ: International Cannabis ponders listing on major international exchange

Other gainers Thursday included Planet 13 Holdings Inc (CSE:PLTH), which continued its rise from earlier in the week. 

On Wednesday, the company reported US$5.49 million in revenue from its Las Vegas Cannabis Entertainment Complex in March 2019, which is the world's largest cannabis dispensary. The company said in March, almost 100,000 people entered the dispensary.

Shares were up 9.5% at C$3.01 in Toronto. 

Duds

Isodiol International Inc (OTCQB:ISOLF) (CSE:ISOL) shares dropped Thursday, down 3.2% to US$1.05. The Vancouver-based company develops hemp-based consumer markets for distribution in Canada, Latin America, Asia, and Europe.

Other laggards on Thursday included Flower One Holdings (CSE:FONE), which was down 5.2% at C$2.75 in Toronto and Newstrike Brands (CVE:HIP), which was down 3.7% at C$0.52. 

 

Contact Katie Lewis at katie@proactiveinvestors.com

]]>
Thu, 04 Apr 2019 11:10:00 -0400 https://www.proactiveinvestors.com/companies/news/217994/buds--duds-cannabis-stocks-slide-on-thursday-cb2-insights-shares-pop-on-acquisition-217994.html
<![CDATA[Media files - CB2 takes huge leap forward signing agreement with Premier Health Group ]]> https://www.proactiveinvestors.com/companies/stocktube/12757/cb2-takes-huge-leap-forward-signing-agreement-with-premier-health-group-12757.html Wed, 27 Mar 2019 15:01:00 -0400 https://www.proactiveinvestors.com/companies/stocktube/12757/cb2-takes-huge-leap-forward-signing-agreement-with-premier-health-group-12757.html <![CDATA[News - CB2 Insights says Premier Health begins adoption of cannabis-focused Clinical Decision Support tool ]]> https://www.proactiveinvestors.com/companies/news/217332/cb2-insights-says-premier-health-begins-adoption-of-cannabis-focused-clinical-decision-support-tool-217332.html CB2 Insights (CSE:CBII) said Wednesday that Premier Health Group Inc (CSE:PHGI) (OTCMKTS:PHGRF), operator of an electronic medical records platform, has begun integration of CB2’s medical cannabis Clinical Decision Support tool.

Under an agreement, more than 4,600 physicians and other healthcare practitioners using Premier Health’s Juno electronic medical records platform will gain access to what CB2 says is the only support tool of its kind. 

The support tool, according to the companies, allows physicians and other healthcare practitioners to draw on clinically validated data in order to overcome barriers they may face related to a lack of access to education, qualification factors, risks and benefits of cannabinoid therapy.

DEEP DIVE: CB2 Insights aims to be a cannabis data leader

“For the past four years, we have worked toward simplifying the process for a physician to determine the appropriateness and potential efficacy of medical cannabis as an option within a patient’s treatment plan,” CB2 CEO Prad Sekar said in a statement. “We are now in a position to benefit from the aggregated and anonymized data gathered from more than 300,000 patient visits in a clinical environment along with the hundreds of clinical trials and observational studies that are collectively used to power our CDS tool."

He added that physicians and others can use the point-of-care application to help them incorporate cannabis as a treatment option.

Toronto-based CB2, through its clinical arm in the US, operates 28 medical cannabis evaluation centers staffed with physicians and other healthcare practitioners.

HIPPA-compliant

CB2 Insights says it complies with the US Health Insurance Portability and Accountability Act in gathering data at the point-of-care to study trends and outcomes.

“We are dedicated to finding new ways to create value for our physician network,” said Dr. Essam Hamza, CEO of Vancouver-based Premier Health. “We continue to receive multiple requests from physicians who ask about how best to incorporate medical cannabis into their clinics. This agreement with CB2 will provide us a robust, validated tool to give our physicians and healthcare practitioners a safe and secure way to qualify, educate and, where appropriate, prescribe medical cannabis to their patients in a compliant manner.”

Share of CB2 Insights slipped C$0.02 to C$0.32 in Wednesday's Canadian trading. Premier Health was up C$0.03 to C$0.77.

–Updates share prices–

Contact Dennis Fitzgerald at dennis@proactiveinvestors.com

]]>
Wed, 27 Mar 2019 08:34:00 -0400 https://www.proactiveinvestors.com/companies/news/217332/cb2-insights-says-premier-health-begins-adoption-of-cannabis-focused-clinical-decision-support-tool-217332.html
<![CDATA[News - CB2 Insights aims to be a cannabis data leader ]]> https://www.proactiveinvestors.com/companies/news/216982/cb2-insights-aims-to-be-a-cannabis-data-leader-216982.html CB2 Insights (CSE:CBII) is a medical cannabis-focused data firm. The Toronto-based company is busy meeting what it says is significant demand by building a data asset covering the medical cannabis sector.

There is a lack of medical cannabis data, according to the company, which is aiming to be a front-runner in filling demand. It proves predictive analytics tools, data-driven software and services. In addition, the company operates 28 cannabis evaluation and education clinics in 12 US states.

When it comes to educating the medical community and having cannabis accepted as a form of medical treatment, clinical trials for cannabis are still years away. For now, much of the data has been anecdotal and, therefore, subjective, according to the company.

WATCH: CB2 Insights acquires medical cannabis clinic group in Colorado and Arizona

CB2 concentrates on real-world evidence obtained from data outside randomized trials and generated during routine clinical practice. The company has created what it says are game-changing tools that engage the medical community and provide the data doctors and other professionals need to recommend with confidence cannabis-based medicines.

The company gathers the data and creates real-world evidence through its proprietary software and clinical service brands. The company says it has collected millions of data points from more than 300,000 patient interactions.

How is it doing? 

CB2 Insights has hit a number of milestons in recent months and started trading on the Canadian Securities Exchange in early March.

Under the company’s umbrella, there are currently three brands: practice management software Sail, used by clinics and general practitioners to evaluate patients for medical cannabis; Canna Care Docs, which provides educational services and evaluations; and TokeIn: a cannabis dispensary loyalty mobile app.

Further acquisitions are in the cards, according to Sekar.

He is aiming to acquire six to eight clinics in 2019, adding that its goal is a 50% compound annual growth rate in clinic revenue for the four-year period from 2018 to 2022.

The company recently acquired MedEval Clinic LLC, a medical cannabis evaluation and education center group with multiple locations in Colorado and Arizona.

READ: CB2 Insights names artificial intelligence pioneer as senior adviser to data insights division

CB2 is is also focused on bolstering its team.

Recently, it announced it had named artificial intelligence (AI) pioneer Dr Randy Goebel as a senior adviser to its data insights division. Goebel will help work on platform architecture and design enhancements to help serve a variety of new stakeholders in the company such as regulatory bodies, government agencies, researchers and pharma firms.

The company recently completed a C$5.74 million non-brokered private placement priced at $0.50 per unit, with each unit consisting of one share at C$0.50 and one-half warrant at C$0.80.

The placement was led by Merida Capital Partners, a New York-based private equity fund that focuses on funding cannabis-related businesses and has invested in a range of cannabis companies including KushCo Holdings Inc (OTCMKTS:KSHB) and GrowGeneration Corp (OTCMKTS:GRWG).

Merida accounted for C$3.68 million of the C$5.74 million raised, according to CB2.

CEO says cannabis efficiacy and outcome data is key

"If cannabis is to play in the same sandbox as other medications and be part of a more traditional healthcare setting at a global capacity what it really needs to have behind it is the type of efficacy data and outcome data that can help to substantiate claims made about cannabis across multiple indications," says CEO Prad Sekar. "For the last four years, CB2 Insights has been developing an infrastructure that's designed around clinical assets, today operating one of the largest networks of medical cannabis evaluation centres in the US."

Contact Katie Lewis at katie@proactiveinvestors.com

 

]]>
Thu, 21 Mar 2019 14:29:00 -0400 https://www.proactiveinvestors.com/companies/news/216982/cb2-insights-aims-to-be-a-cannabis-data-leader-216982.html
<![CDATA[Media files - CB2 Insights acquires medical cannabis clinic group in Colorado and Arizona ]]> https://www.proactiveinvestors.com/companies/stocktube/12666/cb2-insights-acquires-medical-cannabis-clinic-group-in-colorado-and-arizona-12666.html Wed, 20 Mar 2019 16:28:00 -0400 https://www.proactiveinvestors.com/companies/stocktube/12666/cb2-insights-acquires-medical-cannabis-clinic-group-in-colorado-and-arizona-12666.html <![CDATA[News - CB2 Insights strikes deal to acquire MedEval Clinic ]]> https://www.proactiveinvestors.com/companies/news/216843/cb2-insights-strikes-deal-to-acquire-medeval-clinic-216843.html CB2 Insights (CSE:CBII), the medical cannabis-focused data firm, said Wednesday that it has struck a binding agreement to acquire MedEval Clinic LLC, a medical cannabis evaluation and education center group with locations in Colorado and Arizona, for about US$375,000 in cash and stock.

The deal marks the second clinical acquisition for the Toronto company and follows its takeover of Canna Care Docs, the biggest multi-state cannabis clinic group in the US, back in 2017.

MedEval runs two clinics in Colorado with locations in Colorado Springs and Centennial as well as one clinic in Phoenix, Arizona. Set up in 2014, it offers cannabis evaluation and educational services and reported about C$1 million in revenue last year.

Under the agreement's terms, the acquisition will cost CB2 US$150,000 in cash as well as 450,000 of its shares worth a deemed value of US$225,000. Additional milestone incentives are in place, which are valued at up to US$300,000.

READ: CB2 Insights opens new chapter as medical cannabis data supplier begins CSE trading

In a statement, Prad Sekar, CEO of CB2 Insights, said the company is eager to expand in Colorado and Arizona.

“[T]his acquisition not only increases our data pool but has an accretive lift to our financial performance,” said Sekar in a statement. “Colorado plays a vital role in medical cannabis data, representing a very mature recreational market which also sees medical cannabis patient counts continue to grow. … Additionally, Arizona’s untapped market presents a number of opportunities for our company, as the state is primed for growth in the medical cannabis space.”

There is a lack of medical cannabis data, according to CB2 Insights, which is aiming to be a front-runner in filling demand. It proves predictive analytics tools as well as data-driven software and services. In addition, the company operates 28 cannabis evaluation and education clinics in 12 states.

When it comes to educating the medical community and having cannabis accepted as a form of medical treatment, clinical trials for cannabis are still years away. For now, much of the data has been anecdotal and, therefore, subjective, according to the company.

CB2 concentrates on gleaning real-world evidence obtained from data outside randomized trials and generated during routine clinical practice. The company has created what it says are game-changing tools that engage the medical community and provide the data doctors and other professionals need to recommend with confidence cannabis-based medicines.

CB2 Insights currently evaluates 65,000 patients annually through its clinic network and handles millions of clinically validated data points to advance understanding of the effectiveness and risks associated with cannabinoid therapy.

CB2 shares slipped C$0.015 to hit C$0.305 in afternoon trade on Wednesday.

Contact Ellen Kelleher at ellen@proactiveinvestors.com

-- This story was updated to include the price of CB2's MedEval acquisition as well as the latest share price movement--

 

]]>
Wed, 20 Mar 2019 08:03:00 -0400 https://www.proactiveinvestors.com/companies/news/216843/cb2-insights-strikes-deal-to-acquire-medeval-clinic-216843.html
<![CDATA[Media files - CB2 Insight begins trading on the CSE under the ticker symbol CBII ]]> https://www.proactiveinvestors.com/companies/stocktube/12513/cb2-insight-begins-trading-on-the-cse-under-the-ticker-symbol-cbii-12513.html Fri, 08 Mar 2019 15:31:00 -0500 https://www.proactiveinvestors.com/companies/stocktube/12513/cb2-insight-begins-trading-on-the-cse-under-the-ticker-symbol-cbii-12513.html <![CDATA[Media files - CB2 driving to become a leader in Cannabis data ]]> https://www.proactiveinvestors.com/companies/stocktube/11482/cb2-driving-to-become-a-leader-in-cannabis-data-11482.html Wed, 05 Dec 2018 22:51:00 -0500 https://www.proactiveinvestors.com/companies/stocktube/11482/cb2-driving-to-become-a-leader-in-cannabis-data-11482.html